Ixazomib-induced Sweet’s syndrome: A case report

Ixazomib, a proteasome inhibitor commonly used for the treatment of multiple myeloma, is a rare cause of Sweet’s syndrome. We present a 62-year-old man who developed drug-induced Sweet’s syndrome during his fifth cycle of ixazomib for treatment of refractory multiple myeloma. Monthly rechallenge led...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellemare, Jeanne, El Fassy, Hannah Laure, Mereniuk, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
JCMS Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278404/
https://www.ncbi.nlm.nih.gov/pubmed/37342419
http://dx.doi.org/10.1177/2050313X231181034
_version_ 1785060479073255424
author Bellemare, Jeanne
El Fassy, Hannah Laure
Mereniuk, Alexandra
author_facet Bellemare, Jeanne
El Fassy, Hannah Laure
Mereniuk, Alexandra
author_sort Bellemare, Jeanne
collection PubMed
description Ixazomib, a proteasome inhibitor commonly used for the treatment of multiple myeloma, is a rare cause of Sweet’s syndrome. We present a 62-year-old man who developed drug-induced Sweet’s syndrome during his fifth cycle of ixazomib for treatment of refractory multiple myeloma. Monthly rechallenge led to the recurrence of symptoms. The patient was successfully treated with addition of weekly corticosteroids and resumed his cancer treatment.
format Online
Article
Text
id pubmed-10278404
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102784042023-06-20 Ixazomib-induced Sweet’s syndrome: A case report Bellemare, Jeanne El Fassy, Hannah Laure Mereniuk, Alexandra SAGE Open Med Case Rep JCMS Case Report Ixazomib, a proteasome inhibitor commonly used for the treatment of multiple myeloma, is a rare cause of Sweet’s syndrome. We present a 62-year-old man who developed drug-induced Sweet’s syndrome during his fifth cycle of ixazomib for treatment of refractory multiple myeloma. Monthly rechallenge led to the recurrence of symptoms. The patient was successfully treated with addition of weekly corticosteroids and resumed his cancer treatment. SAGE Publications 2023-06-16 /pmc/articles/PMC10278404/ /pubmed/37342419 http://dx.doi.org/10.1177/2050313X231181034 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle JCMS Case Report
Bellemare, Jeanne
El Fassy, Hannah Laure
Mereniuk, Alexandra
Ixazomib-induced Sweet’s syndrome: A case report
title Ixazomib-induced Sweet’s syndrome: A case report
title_full Ixazomib-induced Sweet’s syndrome: A case report
title_fullStr Ixazomib-induced Sweet’s syndrome: A case report
title_full_unstemmed Ixazomib-induced Sweet’s syndrome: A case report
title_short Ixazomib-induced Sweet’s syndrome: A case report
title_sort ixazomib-induced sweet’s syndrome: a case report
topic JCMS Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278404/
https://www.ncbi.nlm.nih.gov/pubmed/37342419
http://dx.doi.org/10.1177/2050313X231181034
work_keys_str_mv AT bellemarejeanne ixazomibinducedsweetssyndromeacasereport
AT elfassyhannahlaure ixazomibinducedsweetssyndromeacasereport
AT mereniukalexandra ixazomibinducedsweetssyndromeacasereport

Ejemplares similares